Talanx lifts 2026 forecast again, targets €3 billion in 2027

More in Business

• STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem

  Investors once anticipated the drugmaker would cross the twelve-figure valuation mark alongside elite peers, but ongoing complications surrounding its cardiac therapy have disrupted that momentum. The setback threatens the long-term commercial upside of its key revenue driver. Resolving these issues remains essential for the biotechnology firm to restore its elite industry standing.

  1 min read
• A look at Nvidia's 10-person board, many of whom have known Jensen Huang for decades, including attorney Stephen Neal, VC Tench Coxe, and academic John Dabiri (Bloomberg)

  The semiconductor giant relies on a ten-member leadership team deeply anchored by multi-decade relationships with Chief Executive Officer Jensen Huang. This governance structure unites trusted advisers from the legal, financial, and educational sectors to help steer corporate strategy. The long-standing personal and professional ties ensure continuity as the company navigates its ongoing industry expansion.

  1 min read
• Billions lost and markets roiled by one man’s indiscretion. Isn’t it now clear that these tech bros are too powerful? | Aditya Chakrabortty

  Massive sell-offs have erased substantial market value from the artificial intelligence chipmaker amid escalating geopolitical and corporate fallout surrounding its top leadership. Revelations linking Jensen Huang to a suspected Chinese intelligence operative have triggered urgent concerns over the security of vital technological infrastructure. The crisis highlights severe vulnerabilities at the semiconductor giant, where intertwined family ties and governance gaps leave leadership succession in question.

  5 min read